MX348262B - Composiciones que comprenden profarmacos opioides con una cetona modificada que se pueden escindir enzimaticamente e inhibidores opcionales de estos. - Google Patents

Composiciones que comprenden profarmacos opioides con una cetona modificada que se pueden escindir enzimaticamente e inhibidores opcionales de estos.

Info

Publication number
MX348262B
MX348262B MX2012002847A MX2012002847A MX348262B MX 348262 B MX348262 B MX 348262B MX 2012002847 A MX2012002847 A MX 2012002847A MX 2012002847 A MX2012002847 A MX 2012002847A MX 348262 B MX348262 B MX 348262B
Authority
MX
Mexico
Prior art keywords
enzyme
ketone
compositions
prodrug
modified opioid
Prior art date
Application number
MX2012002847A
Other languages
English (en)
Other versions
MX2012002847A (es
Inventor
E Jenkins Thomas
D Seroogy Julie
W Wray Jonathan
O Husfeld Craig
Original Assignee
Signature Therapeutics Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signature Therapeutics Inc * filed Critical Signature Therapeutics Inc *
Publication of MX2012002847A publication Critical patent/MX2012002847A/es
Publication of MX348262B publication Critical patent/MX348262B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se describe un método para proporcionar un paciente con liberación controlada de opoide que contienen cetona utilizando un profármaco capaz, tras la activación enzimática y ciclación intramolecular, de liberar el opioide que contiene cetona. La descripción también proporciona tales compuestos de profármacos y composiciones farmacéuticas que comprenden tales compuestos. Tales composiciones farmacéuticas pueden incluir opcionalmente un inhibidor enzimático que interactúa con las enzimas para mediar la liberación controlada enzimáticamente del opioide que contiene cetona del profármaco así como para modificar la separación enzimática del profármaco. También se incluyen métodos para usar tales compuestos y composiciones farmacéuticas.
MX2012002847A 2009-09-08 2010-04-21 Composiciones que comprenden profarmacos opioides con una cetona modificada que se pueden escindir enzimaticamente e inhibidores opcionales de estos. MX348262B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24061109P 2009-09-08 2009-09-08
US28814809P 2009-12-18 2009-12-18
PCT/US2010/031956 WO2011031350A1 (en) 2009-09-08 2010-04-21 Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof

Publications (2)

Publication Number Publication Date
MX2012002847A MX2012002847A (es) 2012-08-23
MX348262B true MX348262B (es) 2017-06-05

Family

ID=43732738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002847A MX348262B (es) 2009-09-08 2010-04-21 Composiciones que comprenden profarmacos opioides con una cetona modificada que se pueden escindir enzimaticamente e inhibidores opcionales de estos.

Country Status (13)

Country Link
US (2) US9493477B2 (es)
EP (1) EP2475429B1 (es)
JP (3) JP2013503862A (es)
CN (1) CN102695545B (es)
AU (1) AU2010293028B2 (es)
BR (1) BR112012005124B1 (es)
CA (1) CA2773340C (es)
IL (1) IL218498A (es)
MX (1) MX348262B (es)
PH (1) PH12012500485A1 (es)
RU (1) RU2600736C2 (es)
SG (1) SG179026A1 (es)
WO (1) WO2011031350A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102695545B (zh) * 2009-09-08 2016-08-17 特色疗法股份有限公司 包括酶可剪切的酮改性的阿片样物质药物前体以及其可任选的抑制剂的组合物
CA2795222A1 (en) * 2010-04-21 2011-10-27 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US9700508B2 (en) 2010-05-10 2017-07-11 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
PH12012502083A1 (en) 2010-05-10 2017-07-26 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
EP2568965A1 (en) 2010-05-10 2013-03-20 Euro-Celtique S.A. Combination of active loaded granules with additional actives
AU2012205733B2 (en) * 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
JP6148182B2 (ja) 2011-03-09 2017-06-14 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. 複素環式リンカーを有する活性薬剤プロドラッグ
US9605296B2 (en) * 2011-09-29 2017-03-28 Ecole Normale Superieure De Lyon Fluorogenic peptidase substrate
SG11201401856VA (en) 2011-10-26 2014-05-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US10626156B2 (en) 2013-12-06 2020-04-21 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
RU2683274C2 (ru) 2014-12-02 2019-03-27 Кемфарм, Инк. Бензойная кислота, производные бензойной кислоты и конъюгаты гетероарилкарбоновой кислоты и оксиморфона, их пролекарства, способы получения и применение
PT3713939T (pt) * 2017-11-24 2021-09-16 Byondis Bv Processo melhorado para a síntese de fármaco ligante vcseco- duba
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020023794A1 (en) * 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
IL305493A (en) 2021-03-09 2023-10-01 Ensysce Biosciences Inc Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof
CN113624665A (zh) * 2021-07-30 2021-11-09 中国药科大学 一种抗肿瘤候选化合物在治疗结直肠癌药物中的应用及测定方法
CA3230025A1 (en) 2021-09-29 2023-04-06 Lynn Kirkpatrick Enzyme-cleavable methadone prodrugs and methods of use thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
US5109118A (en) 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
CA2032420A1 (en) 1989-12-22 1991-06-23 Akira Okuyama Guanidinobenzene derivatives
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US6388122B1 (en) 1996-04-10 2002-05-14 Ono Pharmaceutical Co., Ltd. Tryptase inhibitor and novel guanidino derivatives
ATE441725T1 (de) 1998-12-15 2009-09-15 Applera Corp Multienzym-nachweisverfahren
DE60011053T2 (de) 1999-02-18 2005-05-25 SuperGen, Inc., Dublin An phosphocholin gebundene prodrug-derivate
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
WO2002100353A2 (en) * 2001-06-11 2002-12-19 Medarex, Inc. Cd10-activated prodrug compounds
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
RU2215741C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения
US20100092562A1 (en) 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
SI1644019T2 (en) 2003-05-29 2018-04-30 Shire Llc Abuse resistant amphetamine compounds
EA008864B1 (ru) 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
WO2005042773A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
FR2881363B1 (fr) * 2005-02-02 2008-03-14 Commissariat Energie Atomique Dispositif d'analyses biologiques avec detecteur integre
US8163701B2 (en) 2005-08-19 2012-04-24 Signature Therapeutics, Inc. Prodrugs of active agents
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
EP1934201A1 (en) 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
EP2007762A2 (en) * 2006-04-10 2008-12-31 Shire LLC Mono and di-substituted oxycodone compounds and compositions
EP2007389A2 (en) 2006-04-14 2008-12-31 Shire LLC Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
MX2008014794A (es) 2006-05-26 2009-04-08 Pharmacofore Inc Liberacion controlada de opioides fenolicos.
US20110105381A2 (en) 2007-02-16 2011-05-05 Pharmacofore, Inc. Prodrugs of Peripheral Phenolic Opioid Antagonists
WO2008101202A1 (en) 2007-02-16 2008-08-21 Pharmacofore, Inc. N-17-alkylated prodrugs of opioids
US9023860B2 (en) * 2007-11-26 2015-05-05 Signature Therapeutics, Inc. Pro-drugs for controlled release of biologically active compounds
WO2009080030A1 (en) 2007-12-21 2009-07-02 Lifecycle Pharma A/S Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus
US20090192095A1 (en) * 2008-01-18 2009-07-30 Shire Llc Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects
ES2671897T3 (es) 2008-02-14 2018-06-11 Alkermes, Inc. Compuestos opioides selectivos
US20110046053A1 (en) 2008-05-05 2011-02-24 Oramed Ltd. Methods and compositions for oral administration of exenatide
WO2010045599A1 (en) * 2008-10-17 2010-04-22 Pharmacofore, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
BRPI1015108A2 (pt) 2009-04-02 2016-04-26 Shire Llc pró-fármacos de aminoácidos e peptídios ligados a ácido dicarboxílico de opiáceos e seus usos
WO2011007247A1 (en) 2009-07-17 2011-01-20 Llc Shire Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
CN102695545B (zh) * 2009-09-08 2016-08-17 特色疗法股份有限公司 包括酶可剪切的酮改性的阿片样物质药物前体以及其可任选的抑制剂的组合物
EP2560491A1 (en) 2010-04-21 2013-02-27 Signature Therapeutics, Inc. Peripheral opioid agonists and peripheral opioid antagonists
US20110262355A1 (en) * 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20110262360A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof
CA2795222A1 (en) * 2010-04-21 2011-10-27 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US8497237B2 (en) 2011-01-11 2013-07-30 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
AU2012205733B2 (en) 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
JP6148182B2 (ja) * 2011-03-09 2017-06-14 シグネーチャー セラピューティクス, インク.Signature Therapeutics, Inc. 複素環式リンカーを有する活性薬剤プロドラッグ
WO2012122420A2 (en) * 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers

Also Published As

Publication number Publication date
AU2010293028B2 (en) 2014-12-18
US20120230916A1 (en) 2012-09-13
MX2012002847A (es) 2012-08-23
BR112012005124A2 (pt) 2020-08-25
AU2010293028A1 (en) 2012-04-05
WO2011031350A1 (en) 2011-03-17
BR112012005124B1 (pt) 2021-11-09
EP2475429A4 (en) 2013-04-03
SG179026A1 (en) 2012-04-27
JP2013503862A (ja) 2013-02-04
JP2018172387A (ja) 2018-11-08
JP6778234B2 (ja) 2020-10-28
US9493477B2 (en) 2016-11-15
HK1172283A1 (zh) 2013-04-19
CN102695545A (zh) 2012-09-26
RU2012108874A (ru) 2013-09-20
CA2773340A1 (en) 2011-03-17
PH12012500485A1 (en) 2012-10-22
EP2475429B1 (en) 2015-07-29
RU2600736C2 (ru) 2016-10-27
US20170119754A1 (en) 2017-05-04
CA2773340C (en) 2019-07-23
IL218498A (en) 2017-03-30
CN102695545B (zh) 2016-08-17
JP2016041698A (ja) 2016-03-31
US10028945B2 (en) 2018-07-24
EP2475429A1 (en) 2012-07-18
IL218498A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
SG179026A1 (en) Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
WO2010135524A8 (en) Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
MY167126A (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
PH12013500975A1 (en) Nampt and rock inhibitors
WO2010102071A8 (en) Sustained release oral dosage forms of an r-baclofen prodrug
TN2010000203A1 (en) Beta-lactamase inhibitors
PH12015501470A1 (en) Compositions and methods for the control of nematodes and soil borne diseases
MX366955B (es) Crlx101 para usarse en el tratamiento de cáncer.
MY184914A (en) Methods of administering pirfenidone theraphy
MX342851B (es) Metodos y materiales para sintesis enzimatica de compuestos mogrosido.
MY184008A (en) Aryl pyridine as aldosterone synthase inhibitors
MX2009010568A (es) Formas solidas de pemetrexed.
IN2014CN03597A (es)
GT201100322A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
MX2012001617A (es) Derivados de 5-fluoro-2-oxopirimidina-1 (2h)-carboxamida substituida-n1.
ZA201204583B (en) Degradable removable implant for the sustained release of an active compound
IN2012DN03404A (es)
MX2013005819A (es) Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.
WO2009158646A8 (en) Therapeutic compounds and related methods of use
WO2012099557A3 (en) Fatty acid inhibitors
MX367327B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
MX2013005825A (es) Benzoxazepinas como inhibidores de objetivo de rapamicina en mamiferos (mtor) y metodos de uso y fabricacion.
PH12012500669A1 (en) Processes for the preparation of 2-(1-phenylethyl) isoindolin-1-one compounds
TNSN08531A1 (en) Phenylacetic acid derivatives as cox - 2 inhibitors
MX2012001875A (es) Proceso para la preparación de inhibidores de la catepsina s.

Legal Events

Date Code Title Description
FG Grant or registration